Chemours pulled in $294 million from selling assets and businesses. That is the oddest number in a three-month report where revenue barely moved, and it is the key to reading the rest of the filing.
The surface-level read is cleaner: revenue fell 1.5% to $1.6 billion for the three months ended June 30, while gross profit rose 2.9% to $286 million. The net loss narrowed to $274 million from $380 million, and gross margin improved to 18.0% from 17.2%.
The cash number looks even better. Chemours ended the latest reported period with $671 million in cash, up 33.7% from the comparable period a year earlier. But the company says a disclosed source of investing cash was not product sales or a new operating engine.
"The increase in our investing cash inflows was primarily attributable to $294 million in proceeds from sales of assets and business, primarily due to the net proceeds of the Kuan Yin land sale."
(Chemours, Form 10-[Q](https://jodie.ai/t/Q), Aug. 5, 2026)
That turns the balance-sheet improvement into a more specific fact: Chemours has more cash, but a disclosed part of the investing inflow came from monetizing an asset. The company also reduced inventory 6.8% and accounts receivable 4.9% from the comparable period, while capital spending fell 26.8% and free-cash-flow margin improved by 5.6 percentage points. Those are useful cash-conversion changes, but they do not erase the land-sale distinction.
The operating line shows lower volume alongside higher prices. Chemours disclosed lower volumes in Thermal & Specialized Solutions and Advanced Performance Materials, while higher prices were attributable to Thermal & Specialized Solutions and Titanium Technologies.
"The decrease in volume was primarily driven by lower volumes in Thermal & Specialized Solutions (\"TSS\") and Advanced Performance Materials (\"APM\") segments, while the increase in price was attributable to our TSS and Titanium Technologies (\"TT\") segments."
Chemours, Form 10-Q, Aug. 5, 2026
In plain English, Chemours sold slightly less product and received more per unit in the mix management described. Gross profit rose even as sales slipped. It did not produce a clean return to profit: net margin improved to negative 17.2% from negative 23.5%.
The filing also says lower volumes reduced cost absorption and higher input costs weighed on segment earnings, partly offset by favorable currency movements. The company does not present the quarter as a broad volume recovery. It points instead to early recovery in semiconductors and aerospace, plus growth in electric vehicles and data centers, alongside weaker volumes elsewhere.
That matters against Chemours' recent scale. Annual revenue was $5.8 billion in both 2024 and 2025, while 2025 gross margin was 15.5% and net margin was negative 6.6%. The latest three months show better gross margin and a smaller loss, but the revenue base is still roughly stationary, and the cash increase includes proceeds from an asset transaction.
At the latest close, Chemours shares were $17.93, up 4.9% on Aug. 4. The price move is a market fact, not an explanation of the filing. The unresolved operating question is narrower: how much cash can the business generate without another land sale, while lower volumes and higher input costs remain in the same report?
The next quarterly report's cash-flow detail will provide the next factual comparison. Chemours has not answered the question the current 10-Q leaves hanging: how much of the $671 million cash balance came from operations rather than the Kuan Yin land sale?
The 10-Q leaves one question: how much of Chemours' $671 million cash balance came from operations rather than the Kuan Yin land sale?